Technical Analysis for ALNY - Alnylam Pharmaceuticals, Inc.
Grade | Last Price | % Change | Price Change |
---|---|---|---|
B | 243.32 | 0.13% | 0.32 |
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Up | Up | Up |
Date | Alert Name | Type | % Chg |
---|---|---|---|
Calm After Storm | Range Contraction | 0.00% | |
NR7 | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
Overbought Stochastic | Strength | 0.00% | |
Gapped Down | Weakness | 0.00% | |
Bearish Engulfing | Bearish | 0.13% | |
Slingshot Bullish | Bullish Swing Setup | 0.13% | |
Volume Surge | Other | 0.13% | |
Upper Bollinger Band Walk | Strength | 0.13% | |
Wide Bands | Range Expansion | 0.13% |
Alert | Time |
---|---|
Possible NR7 | about 6 hours ago |
Up 1% | about 10 hours ago |
60 Minute Opening Range Breakout | about 10 hours ago |
Fell Below Previous Day's Low | about 11 hours ago |
Down 1% | about 11 hours ago |
Get a Trading Assistant
- Earnings date: 08/01/2024
Alnylam Pharmaceuticals, Inc. Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Its principal programs under clinical or pre-clinical development include ALN-TTR comprising ALN-TTR02 and ALN-TTRsc for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 for the treatment of hemophilia and rare bleeding disorders; ALN-AS1 for the treatment of acute intermittent porphyria; ALN-PCS for the treatment of hypercholesterolemia; and ALN-TMP for the treatment of hemoglobinopathies, including beta-thalassemia. The company's early stage program comprise ALN-AAT, an RNAi therapeutic targeting the mutant Z-allele in alpha-1-antitrypsin deficiency (AAT deficiency) for the treatment of AAT deficiency-associated liver disease. It also has two partner-based programs in clinical development, including ALN-RSV01 for the treatment of respiratory syncytial virus infection; and ALN-VSP for the treatment of liver cancers, as well as one candidate in pre-clinical development comprising ALN-HTT for the treatment of Huntington's disease. The company has strategic alliances with F. Hoffmann-La Roche Ltd; Arrowhead Research Corporation; Takeda Pharmaceutical Company Limited; Monsanto Company; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Genzyme Corporation; The Medicines Company; Cubist Pharmaceuticals, Inc; Biogen Idec Inc.; and Ascletis Pharmaceuticals (Hangzhou) Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Clinical Development Cholesterol Liver Disease Amyloid Amyloidosis Huntington's Disease Hemoglobin Hemophilia Antitrypsin Deficiency Hypercholesterolemia Spinal Muscular Atrophy Genzyme Rna Interference Alnylam Pharmaceuticals Deficiency Hemophilia A Liver Cancer Thalassemia Therapeutic Gene Modulation Transthyretin Treatment Of Hemophilia Medtronic Acute Intermittent Porphyria Alpha 1 Antitrypsin Deficiency Beta Thalassemia Hemoglobinopathies Monsanto
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 252.87 |
52 Week Low | 141.975 |
Average Volume | 1,009,227 |
200-Day Moving Average | 166.12 |
50-Day Moving Average | 161.59 |
20-Day Moving Average | 180.98 |
10-Day Moving Average | 207.58 |
Average True Range | 9.79 |
RSI (14) | 86.74 |
ADX | 40.77 |
+DI | 54.78 |
-DI | 6.81 |
Chandelier Exit (Long, 3 ATRs) | 223.50 |
Chandelier Exit (Short, 3 ATRs) | 176.16 |
Upper Bollinger Bands | 259.46 |
Lower Bollinger Band | 102.49 |
Percent B (%b) | 0.9 |
BandWidth | 86.74 |
MACD Line | 24.29 |
MACD Signal Line | 15.06 |
MACD Histogram | 9.2319 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 252.64 | ||||
Resistance 3 (R3) | 252.51 | 249.29 | 251.08 | ||
Resistance 2 (R2) | 249.29 | 246.91 | 249.35 | 250.56 | |
Resistance 1 (R1) | 246.30 | 245.45 | 247.80 | 246.43 | 250.05 |
Pivot Point | 243.08 | 243.08 | 243.82 | 243.14 | 243.08 |
Support 1 (S1) | 240.09 | 240.70 | 241.59 | 240.22 | 236.59 |
Support 2 (S2) | 236.87 | 239.24 | 236.93 | 236.08 | |
Support 3 (S3) | 233.88 | 236.87 | 235.56 | ||
Support 4 (S4) | 234.01 |